Search

shutterstock_2261453831(1) (1)

Announcements

Announcements

HOMEWhat’s NewAnnouncements

2025.Apr.23

To announce the press release for material information in a press conference

2025.Apr.23

OBI decided to terminate OBI-822 Phase 3 study based on DSMB's recommendation and to redirect resources towards ADCs development

2025.Apr.22

Announcement on behalf of OBIGEN of Establishment of the Remuneration Committee and Appointment of the First-Term Members

2025.Apr.22

Announcement on behalf of OBIGEN the new replacement of its spokesperson and acting spokesperson

2025.Apr.22

Announcement on behalf of OBIGEN the change of its financial and accounting officer

2025.Apr.01

OBI has submitted the IND application of a Phase I/II human clinical trial for OBI-902 TROP2 ADC to the US FDA

2025.Mar.20

Announcement on behalf of OBIGEN that it has achieved the objectives of interim analysis for Phase 2 clinical trial of OBI-858

2025.Mar.18

Announcement on behalf of OBIGEN that BOD resolved to apply for public offering and listing in the TPEx Emerging Stock Board

2025.Mar.18

Announcement on behalf of OBIGEN that BOD resolved to complete replacement of non-physical stocks

2025.Mar.18

Announcement on behalf of OBIGEN that the BOD resolved to convene the 2025 Annual General Shareholders' Meeting

News

Latest News

Events

Latest events